1 citations
,
May 2017 in “Journal of The American Academy of Dermatology” People with alopecia areata often have lower vitamin D levels than healthy people.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
1 citations
,
October 2014 in “Skin Pharmacology and Physiology” People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.
May 2026 in “Journal of Asia Pacific Aesthetic Sciences” Low-dose intralesional corticosteroid treatment led to rapid hair regrowth in localized alopecia areata.
May 2026 in “Indian Journal of Dermatology” Tofacitinib shows promise for treating alopecia areata with significant hair regrowth and mild side effects.
May 2026 in “International Journal of Homoeopathic Sciences” Individualized Homeopathic Medicine shows promise for treating alopecia with lasting hair regrowth.
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
STS01 1% effectively promotes hair regrowth with minimal side effects.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
March 2026 in “Mendeley Data” Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.
February 2026 in “Australasian Journal of Dermatology” A new tool simplifies alopecia areata severity scoring but needs validation.
February 2026 in “International Journal of Dermatology” Experts recommend specific treatments for alopecia areata based on age and severity, emphasizing the need for better treatments and acknowledging its psychological impact.
February 2026 in “Journal of Cosmetic Dermatology” Combining triamcinolone acetonide with cryotherapy may reduce scalp hair loss more than using triamcinolone alone.
January 2026 in “Dermatologic Therapy” Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
January 2026 in “Dermatologic Therapy” Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
December 2025 in “International Journal of Innovative Technologies in Social Science” Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
November 2025 in “The Bioscan.” Pix Liquida may help treat alopecia areata.
November 2025 in “Journal of Clinical Medicine” Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.
November 2025 in “Figshare” Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.
November 2025 in “The Bioscan.” Pix Liquida helped a man recover from patchy hair loss.
November 2025 in “The Journal of Dermatology” Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective long-term for treating alopecia areata in teens.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
October 2025 in “International Journal of Dermatology” Baricitinib is a safe and effective treatment for alopecia areata, with better results in patients with lower initial severity, shorter disease duration, and longer treatment.
October 2025 in “Journal of Clinical Medicine” Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.